Department of Nephology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Rheumatol Int. 2022 Apr;42(4):749-758. doi: 10.1007/s00296-021-05069-x. Epub 2022 Feb 5.
For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.
在可预见的未来，疫苗是全球对抗新型冠状病毒肺炎（COVID-19）大流行的基石。随着 COVID-19 的病例和死亡人数下降，以及封锁措施无论如何都已解除，我们认识到 COVID-19 疫苗接种后自身免疫性疾病的发病率增加。然而，大多数疫苗引起的副作用的因果关系是有争议的，充其量也仅限于时间上的相关性。我们在此报告一例 51 岁男性，他在 COVID-19 疫苗接种后 2 周出现抗中性粒细胞胞质抗体（ANCA）相关性血管炎（AAV）。患者对口服类固醇和利妥昔单抗反应良好。此外，我们还进行了基于病例的疫苗相关性 AAV 综述，描述了这种新出现实体的临床表现和治疗反应。
